Wyeth licenses Pharmacopeia's JAK3 program

Wyeth Pharmaceuticals has struck a development pact involving Pharmacopeia's JAK3 inhibitor program. The program focuses on the activation of T-cells for rheumatoid arthritis, psoriasis and other immunological conditions. Pharmacopeia retains commercialization rights for the treatment of dermatological and ocular diseases via topical administration while Wyeth gains all other rights in exchange for a $5 million upfront payment, up to $9 million in research funds over three years and up to $175 million in milestone payments.

- here's the release on the licensing deal

Related Articles:
GSK, Pharmacopeia enter discovery alliance. Report
Wyeth, Ablynx ink licensing deal for Nanobodies. Report